

PATENT ATTORNEY DOCKET NO. 50319/003001

Certificate of Mailing: Date of Deposit: February 5, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sarah Wilcox

Printed name of person mailing correspondence

Soul Um

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ribes et al.

Confirmation No.:

1529

Serial No.:

10/069,574

Art Unit:

1614

Filed:

August 1, 2002

Examiner:

Nancy L. Zhang

Customer No.:

21559

Title:

Use of Amino Acids for Making Medicines for Treating to Insulin-

Resistance

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

180.00 DP

Applicants note that an Information Disclosure Statement and a Form PTO-1449 were filed in this case on June 23, 2006, and that they have not yet received an initialed copy of the Form PTO-1449. Applicants thus request an initialed copy of the Form PTO-1449.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: <u>February</u> 5,2007

Susan M. Michaud, Ph.D.

Reg. No. 42,885

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

February 5, 2007

Sheet 1 of 2 50319/003001 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE SUBSTITUTE FORM PTO-1449 (MODIFIED) PATENT AND TRADEMARK OFFICE 10/069,574 Serial No. **Applicant** Ribes et al. INFORMATION DISCLOSURE Filing Date August 1, 2002 STATEMENT BY APPLICANT (Use several sheets if necessary) 1614 Group

(37 C.F.R. § 1.98(b))

U.S. PATENT DOCUMENTS				
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	
				_

IDS Filed

	FOREI	GN PATENT OR PUBLISHE	D FOREIGN PATENT APPLICATION	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Alzaid, "Insulin Resistance in Non-Insulin-Dependent Diabetes Mellitus," Acta Diabetol. 33:87-99, 1996.
Arner et al., "Different Aetiologies of Type 2 (Non-Insulin-Dependent) Diabetes Mellitus in Obese and Non-Obese Subjects," Diabetologia 34:483-487, 1991.
Banerji et al., "Does Intra-Abdominal Adipose Tissue in Black Men Determine Whether NIDDM is Insulin-Resistant or Insulin-Sensitive?" Diabetes 44:141-146, 1995.
Bonora et al., "In Vivo Glucose Metabolism in Obese and Type II Diabetic Subjects With or Without Hypertension," Diabetes 42:764-772, 1993.
Byrne et al., "Elevated Plasma Glucose 2 h Postchallenge Predicts Defects in β-Cell Function," Am. J. Physiol. 270:E572-E579, 1996.
Campbell et al., "Quantification of the Relative Impairment in Actions of Insulin on Hepatic Glucose Production and Peripheral Glucose Uptake in Non-Insulin-Dependent Diabetes Mellitus," Metabolism 37:15-21, 1988.
Gerich, "Insulin Resistance is Not Necessarily an Essential Component of Type 2 Diabetes," J. Clin. Endocrinol. Metab. 85:2113-2115, 2000.
Gerich, 'The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion Versus Impaired Insulin Sensitivity," Endocrine Rev. 19:491-503, 1998.
Groop et al., "Insulin Resistance, Hypertension and Microalbuminuria in Patients with Type 2 (Non-Insulin- Dependent) Diabetes Mellitus," Diabetologia 36:642-647, 1993.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Attorney Docket No.	50319/003001
(MODIFIED)	PATENT AND TRADEMARK OFFICE	Serial No.	10/069,574
11/50PM F10M B100 100 105		Applicant	Ribes et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	August 1, 2002
		Group	1614
(37 C.F.R. § 1.98(b))		IDS Filed	February 5, 2007

 OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
Groop et al., "Insulin Resistance and Insulin Deficiency in the Pathogenesis of Type 2 (Non-Insulin-Dependent) Diabetes Mellitus: Errors of Metabolism or of Methods?" Diabetologia 36:1326-1331, 1993.
Haffner et al., "Insulin Sensitivity and Acute Insulin Response in African-Americans, Non-Hispanic Whites, and Hispanics with NIDDM," Diabetes 46:63-69, 1997.
Kalant et al., "Insulin Responsiveness of Superficial Forearm Tissues in Type 2 (Non-Insulin Dependent) Diabetes," Diabetologia 22:239-244, 1982.
Nesher et al., "Insulin Deficiency and Insulin Resistance in Type 2 (Non-Insulin-Dependent) Diabetes: Quantitative Contributions of Pancreatic and Peripheral Responses to Glucose Homeostasis," Eur. J. Clin. Invest. 17:266-274, 1987.
Nosadini et al., "Impaired Insulin-Induced Glucose Uptake by Extrahepatic Tissue is Hallmark of NIDDM Patients Who Have or Will Develop Hypertension and Microalbuminuria," Diabetes 43:491-499, 1994.
O'Rahilly et al., "Beta-Cell Dysfunction, Rather than Insulin Insensitivity, is the Primary Defect in Familial Type 2 Diabetes," Lancet 2:360-364, 1986.
Pigon et al., "Normal Hepatic Insulin Sensitivity in Lean, Mild Noninsulin-Dependent Diabetic Patients," J. Clin. Endocrinol. Metab. 81:3702-3708, 1996.
Strutton et al., "Estimated Coronary Heart Disease Attributable to Insulin Resistance in Populations With and Without Type 2 Diabetes Mellitus," Am. J. Manag. Care 7:765-773, 2001.
Taniguchi et al., "Insulin Sensitivity, Insulin Secretion, and Glucose Effectiveness in Obese Subjects: a Minimal Model Analysis," Metabolism 44:1397-1400, 1995.

EXAMINER DATE CON	NSIDERED
-------------------	----------